Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:4.6.1.1 (
adenylate cyclase
)
19,190
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
In addition to the pituitary, prolactin (PRL) in humans is produced at non-pituitary sites where it acts as a cytokine. We previously reported that PRL is expressed and released from breast adipose explants, raising the question as to the dynamics of its production and its regulation. Preadipocytes were isolated from breast adipose tissue obtained during breast reduction. PRL expression was transiently increased during early preadipocyte differentiation. Both isoproterenol, a beta-adrenergic receptor agonist, and
PACAP
, pituitary
adenylate cyclase
activating peptide, increased PRL expression, and release from preadipocytes. This stimulation was suppressed by several protein kinase inhibitors, suggesting involvement of multiple signaling pathways. Transfection of preadipocytes with a superdistal PRL promoter/luciferase reporter revealed two stimulatory domains and an inhibitory domain. These data establish the transcriptional regulation of adipocyte PRL by the superdistal PRL promoter, its transient expression during adipogenesis, and the stimulatory effect of catecholamines and
PACAP
.
...
PMID:Induction of prolactin expression and release in human preadipocytes by cAMP activating ligands. 1663 May 38
PACAP
inhibits cell proliferation and promotes cell survival and neurite outgrowth of pheochromocytoma PC12 cells. Transcriptome analysis of
PACAP
-treated PC12 cells allowed to identify potential genes implicated in this differentiation process. Among the genes whose expression is up-regulated by
PACAP
, we identified the Inhibitor of DNA binding 3 (Id3). Id3 is a member of the helix-loop-helix (HLH) family of transcription factors which acts as a negative dominant inhibitor of basic HLH factors. Time-course studies revealed that Id3 is an early
PACAP
response gene (8-fold after 1 h of stimulation), and that the up-regulation of its expression persists over 12 h after the onset of
PACAP
treatment. The stimulatory effect of
PACAP
on Id3 mRNA levels was mimicked by
adenylate cyclase
/PKA activators like forskolin and dibutyryl cyclic AMP. Moreover,
PACAP
-induced Id3 gene expression was inhibited by phosphatidylinositol 3'-OH-kinase and p38 MAP kinase blockers. Northern blot analysis of Id3 distribution in rat tissues showed a strong expression of this gene in the adrenal medulla. Overexpression of Id3 increased the number of living PC12 cells, in basal condition and after exposure to oxidative stress. These results indicate that Id3 is a cAMP-responsive gene whose up-regulation could be involved in
PACAP
-induced pro-survival signaling during sympathoadrenal cell differentiation.
...
PMID:Possible implication of the transcriptional regulator Id3 in PACAP-induced pro-survival signaling during PC12 cell differentiation. 1692 5
The mammalian master clock, located in the suprachiasmatic nucleus (SCN), is exquisitely sensitive to photic timing cues, but the key molecular events that sculpt both the phasing and magnitude of responsiveness are not understood. Here, we show that the Ras-like G-protein Dexras1 is a critical factor in these processes. Dexras1-deficient mice (dexras1-/-) exhibit a restructured nighttime phase response curve and a loss of gating to photic resetting during the day. Dexras1 affects the photic sensitivity by repressing or activating time-of-day-specific signaling pathways that regulate extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase (MAPK). During the late night, Dexras1 limits the capacity of pituitary
adenylate cyclase
(PAC) activating peptide (
PACAP
)/PAC1 to affect ERK/MAPK, and in the early night, light-induced phase delays, which are mediated predominantly by NMDA receptors, are reduced as reported previously. Daytime photic phase advances are mediated by a novel signaling pathway that does not affect the SCN core but rather stimulates ERK/MAPK in the SCN shell and triggers downregulation of clock protein expression.
...
PMID:The molecular gatekeeper Dexras1 sculpts the photic responsiveness of the mammalian circadian clock. 1716 88
We have identified the single PAC1 receptor variant responsible for Ca2+ mobilization from intracellular stores and influx through voltage-gated Ca2+ channels in bovine chromaffin cells and the domain of this receptor variant that confers coupling to [Ca2+]i elevation. This receptor (bPAC1hop) contains a 28-amino acid "hop" insertion in the third intracellular loop, with a full-length 171-amino acid N terminus. Expression of the bPAC1hop receptor in NG108-15 cells, which lack endogenous PAC1 receptors, reconstituted high affinity
PACAP
binding and
PACAP
-dependent elevation of both cAMP and intracellular Ca2+ concentrations ([Ca2+]i). Removal of the hop domain and expression of this receptor (bPAC1null) in NG108-15 cells reconstituted high affinity
PACAP
binding and
PACAP
-dependent cAMP generation but without a corresponding [Ca2+]i elevation. PC12-G cells express sufficient levels of PAC1 receptors to provide
PACAP
-saturable coupling to
adenylate cyclase
and to drive
PACAP
-dependent differentiation but do not express PAC1 receptors at levels found in postmitotic neuronal and endocrine cells and do not support
PACAP
-mediated neurosecretion. Expression of bPAC1hop, but not bPAC1(null), at levels comparable with those of bPAC1hop in bovine chromaffin cells resulted in acquisition by PC12-G cells of
PACAP
-dependent [Ca2+]i increase and extracellular Ca2+ influx. In addition, PC12-G cells expressing bPAC1hop acquired the ability to release [3H]norepinephrine in a Ca2+ influx-dependent manner in response to
PACAP
. Expression of
PACAP
receptors in neuroendocrine rather than nonneuroendocrine cells reveals key differences between PAC1hop and PAC1null coupling, indicating an important and previously unrecognized role of the hop cassette in PAC1-mediated Ca2+ signaling in neuroendocrine cells.
...
PMID:The hop cassette of the PAC1 receptor confers coupling to Ca2+ elevation required for pituitary adenylate cyclase-activating polypeptide-evoked neurosecretion. 1721 3
Pituitary adenylate cyclase-activating polypeptide (
PACAP
, ADCYAP1:
adenylate cyclase
-activating polypeptide 1), a neuropeptide with neurotransmission modulating activity, is a promising schizophrenia candidate gene. Here, we provide evidence that genetic variants of the genes encoding
PACAP
and its receptor, PAC1, are associated with schizophrenia. We studied the effects of the associated polymorphism in the
PACAP
gene on neurobiological traits related to risk for schizophrenia. This allele of the
PACAP
gene, which is overrepresented in schizophrenia patients, was associated with reduced hippocampal volume and poorer memory performance. Abnormal behaviors in
PACAP
knockout mice, including elevated locomotor activity and deficits in prepulse inhibition of the startle response, were reversed by treatment with an atypical antipsychotic, risperidone. These convergent data suggest that alterations in
PACAP
signaling might contribute to the pathogenesis of schizophrenia.
...
PMID:Pituitary adenylate cyclase-activating polypeptide is associated with schizophrenia. 1738 18
The vasoactive intestinal peptide/pituitary
adenylate cyclase
-activating peptide (VIP/
PACAP
) system is considered as a paradigm for the use of a neuroendocrine-immune mediator in therapy. We review the role of VIP in 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colitis as a murine model of Crohn's disease. VIP treatment led to the recovery of clinical factors, the amelioration of parameters related to the recruitment and traffic of cell populations, and the balance of inflammatory mediators derived from granulocytes, antigen-presenting cells and T lymphocytes including Th1, Th2 and Th17. Finally, the most recent data validate its therapeutic role through the modulation of TLR2 and 4 receptors.
...
PMID:Vasoactive intestinal peptide as a healing mediator in Crohn's disease. 1866 99
The effects of intracerebroventricular (i.c.v.) administration of pituitary
adenylate cyclase
activating polypeptide38 (PACAP38) on prolactin (PRL) secretion and the activity of tyrosine hydroxylase (TH) were examined in adult male and lactating rats with or without suckling stimulus. In adult male rats and lactating rats with suckling stimulus, administration of PACAP38 (0.25 or 1 nmol) decreased PRL secretion and increased the activity of TH in the stalk-median eminence. On the other hand, the injection of PACAP38 did not affect PRL secretion and TH activity in lactating rats without sucking stimulus. Administration of PACAP6-38 (4 nmol), a specific receptor antagonist, also had no effect on PRL secretion and TH activity in adult male rats. These results suggest that i.c.v. administration of
PACAP
inhibits PRL secretion mediated by dopamine neuron within the hypothalamus, but the effects of
PACAP
differ depending on the physiological condition of animals. These observed effects of
PACAP
on PRL release may be pharmacological responses rather than physiological responses.
...
PMID:The different effects of i.c.v. injection of pituitary adenylate cyclase activating polypeptide (PACAP) on prolactin secretion in adult male and lactating rats. 1989 32
Pituitary adenylate cyclase-activating polypeptide (
PACAP
, ADCYAP1:
adenylate cyclase
-activating polypeptide 1) is a neuropeptide with neurotransmission modulating activity. The associations of the
PACAP
gene with schizophrenia and hippocampal volume have been reported. We recently reported depression-like behavior in the forced swimming test in
PACAP
deficient mice. Here we examined a possible association between the
PACAP
gene and major depressive disorder (MDD) in 637 patients and 967 controls and found that a genetic variant in the gene was associated with MDD. The present results suggest that
PACAP
signaling might contribute to the pathogenesis of MDD.
...
PMID:Possible association between the pituitary adenylate cyclase-activating polypeptide (PACAP) gene and major depressive disorder. 1991 36
Activity of the
adenylate cyclase
signaling system was evaluated in the testicular tissue of rats with neonatal streptozotocin-induced diabetes (120 and 180 days duration). This state is similar to type 2 diabetes in humans. The regulation of this system by polypeptide hormones and biogenic amines was studied. Sensitivity of the
adenylate cyclase
signaling system to the regulatory effect of human chorionic gonadotropin and
PACAP
(pituitary adenylyl cyclase-activating polypeptide) was significantly reduced. The effects of these agents are realized via stimulatory G proteins. Somatostatin, acting through inhibitory G proteins, produced less pronounced effect on the
adenylate cyclase
signaling system. The increase in the duration of diabetes was accompanied by a decrease in the stimulatory effects of human chorionic gonadotropin and
PACAP
on
adenylate cyclase
. Sensitivity of the
adenylate cyclase
signaling system to biogenic amines remained unchanged (serotonin) or increased under these conditions (epinephrine). Our results indicate that changes in hormonal regulation of the
adenylate cyclase
signaling system and functional activity of cAMP-dependent signaling cascades are important factors for dysfunction of spermatogenesis and steroidogenesis during insulin-independent diabetes.
...
PMID:Changes in hormone sensitivity of the adenylate cyclase signaling system in the testicular tissue of rats with neonatal streptozotocin-induced diabetes. 2039 97
PACAP
is a highly conserved
adenylate cyclase
(AC) activating polypeptide, which, along with its receptors (PAC1-R, VPAC1, and VPAC2), is expressed in both vertebrate and invertebrate nervous systems. In vertebrates,
PACAP
has been shown to be involved in associative learning, but it is not known if it plays a similar role in invertebrates. To prepare the way for a detailed investigation into the possible role of
PACAP
and its receptors in a suitable invertebrate model of learning and memory, here, we undertook a study of their expression and biochemical role in the central nervous system of the pond snail Lymnaea stagnalis. Lymnaea is one of the best established invertebrate model systems to study the molecular mechanisms of learning and memory, including the role of cyclic AMP-activated signaling mechanisms, which crucially depend on the learning-induced activation of AC. However, there was no information available on the expression of
PACAP
and its receptors in sensory structures and central ganglia of the Lymnaea nervous system known to be involved in associative learning or whether or not
PACAP
can actually activate AC in these ganglia. Here, using matrix-assisted laser desorption ionization time of flight (MALDI-TOF) and immunohistochemistry, we established the presence of
PACAP
-like peptides in the cerebral ganglia and the lip region of Lymnaea. The MALDI-TOF data indicated an identity with mammalian PACAP-27 and the presence of a squid-like PACAP-38 highly homologous to vertebrate PACAP-38. We also showed that
PACAP
, VIP, and maxadilan stimulated the synthesis of cAMP in Lymnaea cerebral ganglion homogenates and that this effect was blocked by the appropriate general and selective PACAP receptor antagonists.
...
PMID:Pituitary adenylate cyclase activating polypeptide (PACAP) and its receptors are present and biochemically active in the central nervous system of the pond snail Lymnaea stagnalis. 2039 76
<< Previous
1
2
3
4
5
6
7
8
9
10